Abstract
Justify universal adoption of intracameral antibiotic for prophylaxis against postcataract endophthalmitis. Review of both placebo-controlled randomized clinical trials for intracameral cefuroxime and moxifloxacin as well as large retrospective studies demonstrate efficacy in reducing the risk of postcataract endophthalmitis when the intracameral antibiotic choice is targeted to the causative pathogens of the demographic studied. Clinical evidence demonstrates the benefit of intracameral antibiotic use from statistical, clinical, and cost-effective analyses. Cases with higher risk for endophthalmitis such as posterior capsule rupture, manual extracapsular cataract extraction, immunocompromised patients, and age > 85, warrant special attention and greater consideration for intracameral antibiotic use. Further research to identify the optimal drug, formulation, and concentration can improve patient outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
